Comparative Pharmacology
Head-to-head clinical analysis: METROGEL versus METROGEL VAGINAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METROGEL versus METROGEL VAGINAL.
METROGEL vs METROGEL-VAGINAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.
None Documented
None Documented
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Terminal elimination half-life: 6-8 hours (prolonged in hepatic impairment; half-life may exceed 20 hours in severe hepatic disease)
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
Renal: 60-80% unchanged; fecal/biliary: 6-15%
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)